We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Spark Therapeutics Proposes Value-Based Reimbursement, Installment Plans for Luxturna
Spark Therapeutics Proposes Value-Based Reimbursement, Installment Plans for Luxturna
Amid controversy over the high cost of its newly approved gene therapy Luxturna — $850,000 before discounts — Spark Therapeutics announced a series of initiatives to improve patient access to the drug, including outcomes-based arrangements with Harvard Pilgrim and Express Scripts.